Table 4.

Relationship between the 3-gene classifier and other variables

Variables	3-Gene classifier
	Discovery Cohort A (N = 83)					Validation Cohort B (N = 75)
	Low (N = 34; 41 %)		High (N = 49; 59 %)			Low (N = 63; 84 %)		High (N = 12; 16 %)
	N	%	N	%	p	N	%	N	%	p
Menopausal status
Premenopausal	20	60	23	47		24	38	4	33	0.75
Postmenopausal	13	40	26	53	0.22	39	62	8	67
Primary tumor grades
2	20	67	15	33		28	49	6	50	0.95
3	10	33	30	67	0.05	29	51	6	50
ER
Negative	16	47	36	75		35	56	8	67	0.47
Positive	18	53	12	25	0.01	28	44	4	33
PR
Negative	23	68	36	75		45	71	9	75	0.80
Positive	11	32	12	25	0.46	18	29	3	25
Induction chemotherapy
No	21	62	28	58		50	79	5	42	0.007
Yes	13	38	20	42	0.75	13	21	7	58
Endocrine therapy
No	12	36	31	63		33	52	8	67	0.36
Yes	22	65	18	37	0.01	30	48	4	33
Trastuzumab for metastatic disease
No	3	9	13	26		15	24	2	17	0.59
Yes	31	91	36	73	0.04	48	76	10	83
Visceral location of first relapse
No	31	94	34	69		44	73	9	75	0.90
Yes	2	6	15	31	0.01	16	27	3	25
First site of visceral metastasis
Lung	11	33	12	25		22	37	3	25	0.05
Liver	16	48	18	37		22	37	4	33
Other	2	6	13	27		13	22	2	17
Lung and liver	4	12	4	8		0	0	2	17
Lung and other	0	0	0	0		2	3	1	8
Liver and other	0	0	2	4	0.19	1	2	0	0
Brain metastases
No	11	32	25	51		28	44	6	50
Yes	23	67	24	49	0.09	35	55	6	50	0.72

Significant values marked in bold

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2